Sevabertinib Approval Narrows HER2-Mutated NSCLC Use

The indication is molecularly and clinically narrow

The September 2026 decision makes sevabertinib available for adults with locally advanced or metastatic non-squamous non-small cell lung cancer whose tumors carry an activating mutation in the HER2 tyrosine kinase domain. The mutation must be detected using an FDA-approved test, and the indication applies after prior systemic therapy.

Each part of that wording matters. The approval does not encompass squamous NSCLC, earlier-stage disease that can be treated definitively, or first-line use. Nor does it establish sevabertinib as a treatment for every tumor described as “HER2-positive.” HER2 protein overexpression, ERBB2 gene amplification and an activating ERBB2 mutation are distinct biomarkers and are not interchangeable for this indication.

HER2 is encoded by ERBB2. The relevant alterations occur in the receptor’s intracellular tyrosine kinase domain, where certain substitutions, insertions or duplications can activate signaling. Exon 20 insertions account for many oncogenic HER2 mutations in lung cancer, but a clinician should not assume that every ERBB2 variant in exon 20—or elsewhere in the kinase domain—meets the approved definition.

The operational standard is the FDA-approved companion test and its labeling. A report must identify a variant that the authorized assay classifies within the qualifying HER2 tyrosine kinase domain activating-mutation category. Amplification alone, high immunohistochemical expression alone, extracellular-domain mutations and variants of uncertain significance do not establish eligibility under the approved indication.

What supported accelerated approval

The FDA based the decision on antitumor activity observed in patients with previously treated, locally advanced or metastatic non-squamous NSCLC harboring qualifying HER2 tyrosine kinase domain activating mutations. Accelerated oncology approvals commonly rely on objective response rate and duration of response when those measures are considered reasonably likely to predict clinical benefit.

This evidence is not equivalent to a randomized demonstration that sevabertinib improves overall survival, progression-free survival or quality of life compared with another therapy. Without a concurrent control group, response outcomes cannot establish the size of any comparative benefit, and differences between studies should not be treated as head-to-head evidence.

The FDA notice is the primary regulatory record for the evaluable cohort, objective response rate, confidence interval and response durability used in the decision. Those numerical results, along with the safety population and adverse-event frequencies, should be transcribed directly from the final notice and prescribing information before clinical publication or formulary review. They should not be inferred from conference reports, earlier data cuts or studies of other HER2-directed drugs.

The distinction is particularly important in a rapidly changing treatment landscape. Results for antibody-drug conjugates or other HER2-selective tyrosine kinase inhibitors cannot be transferred to sevabertinib. Differences in enrolled populations, prior treatment, mutation spectrum, central review, follow-up and management of brain metastases can materially affect observed response rates and duration.

Testing determines whether the label applies

The approval raises a practical testing issue: a generic positive result for “HER2 alteration” is insufficient. Reports should specify the gene, transcript, protein-level consequence, alteration type and assay interpretation. The laboratory report should also make clear whether the finding is a validated activating tyrosine kinase domain mutation covered by the FDA-approved test.

Comprehensive next-generation sequencing is often the most efficient way to identify ERBB2 mutations in advanced non-squamous NSCLC because it can assess multiple actionable drivers simultaneously. Tissue remains important, but plasma cell-free DNA can be useful when tissue is unavailable or inadequate. A negative plasma result does not necessarily exclude a tumor mutation, particularly when circulating tumor DNA shedding is low; tissue testing may still be informative when clinically feasible.

The exact assay claim matters for policy as well as bedside decisions. Laboratories, health systems and payers should distinguish analytical detection of an ERBB2 variant from regulatory qualification for sevabertinib. If a local panel detects a rare kinase-domain variant outside the companion test’s stated coverage, the result may require laboratory clarification or confirmation rather than automatic treatment assignment.

Repeat testing may also be relevant when an earlier assay did not cover ERBB2 adequately, used limited hotspot methods or returned insufficient material. The approval does not, however, mean that serial testing is necessary solely to reconfirm a clearly documented qualifying mutation.

What accelerated approval does—and does not—mean

Accelerated approval is full legal authorization for the labeled indication, but it is conditional on further evidence. The pathway permits earlier availability based on a surrogate or intermediate endpoint reasonably likely to predict clinical benefit in a serious disease with unmet need. It is not a finding that long-term benefit has already been established.

The sponsor must complete postapproval confirmatory work designed to verify clinical benefit. Depending on the FDA requirement, that evidence may need to characterize outcomes in a larger or more representative population, compare sevabertinib with an appropriate treatment, or establish benefit using endpoints such as progression-free or overall survival. The agency can revise or withdraw an indication if confirmatory evidence fails to verify benefit or required studies are not conducted with due diligence.

Project Confirm reflects the FDA Oncology Center of Excellence’s effort to make oncology accelerated-approval status and confirmatory obligations more transparent. Clinicians, guideline groups, payers and pharmacy committees should therefore track the indication after launch rather than treating the initial decision as the final evidentiary endpoint.

Important limits on interpretation

The central limitation is the reliance on response-based evidence from a nonrandomized population. Selection criteria can produce a group that differs from routine practice in performance status, organ function, prior therapies, central nervous system disease and access to molecular testing. Small molecularly defined cohorts also yield imprecise estimates, especially for uncommon mutation subtypes.

Generalizability across the full range of HER2 kinase-domain mutations remains uncertain unless variant-level enrollment and outcomes are reported. Longer follow-up is needed to define response durability, resistance, intracranial activity, cumulative toxicity and sequencing after other HER2-directed treatment. Accelerated approval supports use within the label; it does not resolve the optimal order of available therapies.

Questions clinicians ask

Does any pathogenic ERBB2 mutation qualify?

No. The label is limited to activating mutations in the HER2 tyrosine kinase domain detected by an FDA-approved test. A pathogenic designation on a broad sequencing report does not by itself show that the variant falls within the companion diagnostic claim, particularly for extracellular-domain alterations or variants with uncertain activating function.

Are HER2 amplification and HER2 overexpression enough?

No. ERBB2 amplification, HER2 protein overexpression and HER2 activating mutations are different biomarkers. For sevabertinib under this indication, amplification or overexpression without a qualifying tyrosine kinase domain activating mutation does not establish eligibility.

Can sevabertinib be used as initial systemic therapy?

The accelerated approval described by the FDA is for the previously treated, locally advanced or metastatic setting. It should not be read as evidence for perioperative, definitive-stage or first-line use unless those settings are separately supported by a label expansion or applicable clinical trial.

What evidence must come next?

The sponsor must verify clinical benefit through FDA-required confirmatory evidence. Until mature comparative outcomes are available, response rate and duration should be interpreted as the basis for conditional approval rather than proof of improved survival or quality of life over another treatment.

References

1. FDA Grants Accelerated Approval to Sevabertinib for HER2-Mutated Non-Squamous NSCLC — US Food and Drug Administration, 2026
2. Accelerated Approval Program — US Food and Drug Administration, 2026
3. Project Confirm — US Food and Drug Administration, 2026